Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VA INTREPID: Rifampin for Diabetic Foot Osteomyelitis
NCT03012529Phase 4Completed
- Sponsor
- VA Office of Research & Development
- Start
- Jan 2018
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of rifampicin in osteomyelitis (OM), sponsored by VA Office of Research & Development. Started Jan 2018; status: completed.
02
Drugs
rifampicin
03
Conditions
osteomyelitis (OM)
Beyond the preview
Go deeper on NCT03012529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03012529.